title: Production of transgenic mice from vitrified pronuclear-stage embryos.
abstract: Cryopreservation of pronuclear-stage embryos would be useful for transgenic technology and genome preservation purposes. We compared a novel vitrification technique (solid surface vitrification, SSV) with another vitrification method in straws for cryosurvival and to generate transgenic progeny from cryopreserved mouse zygotes following microinjection. The SSV solution consisted of 35% ethylene glycol (EG), 5% polyvinyl-pyrrolidone (PVP), and 0.4 M trehalose in M2 supplemented with 4 mg/ml BSA; the in straw vitrification solution was 7 M EG in M2 plus BSA. In experiment I, we compared the effect of the vitrification solutions alone, without cooling. No reduction was detected in survival and cleavage rates. In experiment II, SSV yielded a significantly higher percentage of morphologically normal zygotes (96%) that also cleaved at significantly higher rates (80%) when compared to that following "in straw" vitrification (68 and 66%, respectively). Cleavage rate in the non-vitrified control group (93%) was significantly higher than that of both vitrified groups. Following embryo transfer, there was no difference in the rate of pups obtained from the SSV, "in straw" vitrified, and control groups (97/457, 21%; 15/75, 20% and 56/209, 27%, respectively). In experiment III, SSV vitrified and fresh embryos were used for pronuclear DNA injection. Survival rate of vitrified embryos after microinjection was reduced compared to nonvitrified ones (64 vs. 72%, respectively; P < 0.05); however, development to two-cell stage was not different (76 vs. 72%, respectively). Following embryo transfer of vitrified vs. fresh microinjected embryos, in both cases 10% live pups were generated, including transgenic pups. The results demonstrated that the efficiency of generating transgenic pups from SSV vitrified pronuclear zygotes is comparable to that from fresh embryos.
authors.affiliation: Tübitak, Marmara Research Center, Research Institute for Genetic Engineering and Biotechnology, Transgenic Core Facility, Kocaeli, Turkey. haydar@rigeb.gov.tr
authors.forename: H
authors.initials: H
authors.lastname: Bagis
authors.forename: H
authors.initials: H
authors.lastname: Odaman
authors.forename: H
authors.initials: H
authors.lastname: Sagirkaya
authors.forename: A
authors.initials: A
authors.lastname: Dinnyés
mesh_terms: D000818:Animals; D002417:Cattle; D015925:Cryopreservation / Q000379:methods*; D003451:Cryoprotective Agents / Q000494:pharmacology; D005260:Female; D051379:Mice; D008822:Mice, Transgenic; D008845:Microinjections; D011247:Pregnancy; D015053:Zygote / Q000187:drug effects / Q000502:physiology*; D017388:Zygote Intrafallopian Transfer / Q000379:methods*
chemical_list: D003451:Cryoprotective Agents